Nipradilol, a new β‐blocker with vasodilatory properties, in experimental portal hypertension

A comparative haemodynamic study with propranolol

Soon-Ho Um, OSAMU NISHIDA, MASAKI TOKUBAYASHI, FUMIKO KIMURA, TORU KITA

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The haemodynamic effects of nipradilol, a new non‐selective β‐adrenoreceptor blocker with vasodilating actions like nitroglycerin, were examined in rats with portal hypertension due to portal vein stenosis. Portal hypertensive rats were divided into five groups receiving infusion of placebo, 3 mg of propranolol, 300, 600 and 1200 μg of nipradilol. At its highest dose, nipradilol achieved a reduction of 34.4 ± 4.4% in heart rate which was similar to that in the propranolol group (36.5 ± 2.4%). Also for other systemic haemodynamic parameters, the nipradilol 1200 μg group exhibited changes not significantly different from those in the propranolol group; mean arterial pressure (‐ 13 vs ‐ 14%), cardiac index (‐ 37 vs ‐ 31%) and systemic vascular resistance (+ 29 vs+ 32%). In contrast to the similar changes in the systemic circulation, a 1200 μg dose of nipradilol lowered portal pressure significantly more than propranolol (‐ 4.3 ± 0.6 vs ‐ 2.9 ± 0.2 mmHg, P≤ 0.05). Nipradilol then reduced portal blood flow by 22% (P≤ 0.05) without a significant change in portocollateral resistance. On the other hand, propranolol not only caused a reduction in portal blood flow of 30% (P≤ 0.01), but also an increase in portocollateral resistance of 21% (P≤ 0.05). The results suggest that nipradilol may ensure a more effective control of portal hypertension than propranolol, presumably via its venodilatory action on portocollateral vessels.

Original languageEnglish
Pages (from-to)414-419
Number of pages6
JournalJournal of Gastroenterology and Hepatology
Volume8
Issue number5
DOIs
Publication statusPublished - 1993 Jan 1
Externally publishedYes

Fingerprint

Portal Hypertension
Propranolol
Hemodynamics
Portal Pressure
Nitroglycerin
Portal Vein
nipradilol
Vascular Resistance
Arterial Pressure
Pathologic Constriction
Heart Rate
Placebos

Keywords

  • nipradilol
  • portal hypertension
  • propranolol

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Nipradilol, a new β‐blocker with vasodilatory properties, in experimental portal hypertension : A comparative haemodynamic study with propranolol. / Um, Soon-Ho; NISHIDA, OSAMU; TOKUBAYASHI, MASAKI; KIMURA, FUMIKO; KITA, TORU.

In: Journal of Gastroenterology and Hepatology, Vol. 8, No. 5, 01.01.1993, p. 414-419.

Research output: Contribution to journalArticle

@article{f5b467f33bda4d35b86ee09299a52952,
title = "Nipradilol, a new β‐blocker with vasodilatory properties, in experimental portal hypertension: A comparative haemodynamic study with propranolol",
abstract = "The haemodynamic effects of nipradilol, a new non‐selective β‐adrenoreceptor blocker with vasodilating actions like nitroglycerin, were examined in rats with portal hypertension due to portal vein stenosis. Portal hypertensive rats were divided into five groups receiving infusion of placebo, 3 mg of propranolol, 300, 600 and 1200 μg of nipradilol. At its highest dose, nipradilol achieved a reduction of 34.4 ± 4.4{\%} in heart rate which was similar to that in the propranolol group (36.5 ± 2.4{\%}). Also for other systemic haemodynamic parameters, the nipradilol 1200 μg group exhibited changes not significantly different from those in the propranolol group; mean arterial pressure (‐ 13 vs ‐ 14{\%}), cardiac index (‐ 37 vs ‐ 31{\%}) and systemic vascular resistance (+ 29 vs+ 32{\%}). In contrast to the similar changes in the systemic circulation, a 1200 μg dose of nipradilol lowered portal pressure significantly more than propranolol (‐ 4.3 ± 0.6 vs ‐ 2.9 ± 0.2 mmHg, P≤ 0.05). Nipradilol then reduced portal blood flow by 22{\%} (P≤ 0.05) without a significant change in portocollateral resistance. On the other hand, propranolol not only caused a reduction in portal blood flow of 30{\%} (P≤ 0.01), but also an increase in portocollateral resistance of 21{\%} (P≤ 0.05). The results suggest that nipradilol may ensure a more effective control of portal hypertension than propranolol, presumably via its venodilatory action on portocollateral vessels.",
keywords = "nipradilol, portal hypertension, propranolol",
author = "Soon-Ho Um and OSAMU NISHIDA and MASAKI TOKUBAYASHI and FUMIKO KIMURA and TORU KITA",
year = "1993",
month = "1",
day = "1",
doi = "10.1111/j.1440-1746.1993.tb01540.x",
language = "English",
volume = "8",
pages = "414--419",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Nipradilol, a new β‐blocker with vasodilatory properties, in experimental portal hypertension

T2 - A comparative haemodynamic study with propranolol

AU - Um, Soon-Ho

AU - NISHIDA, OSAMU

AU - TOKUBAYASHI, MASAKI

AU - KIMURA, FUMIKO

AU - KITA, TORU

PY - 1993/1/1

Y1 - 1993/1/1

N2 - The haemodynamic effects of nipradilol, a new non‐selective β‐adrenoreceptor blocker with vasodilating actions like nitroglycerin, were examined in rats with portal hypertension due to portal vein stenosis. Portal hypertensive rats were divided into five groups receiving infusion of placebo, 3 mg of propranolol, 300, 600 and 1200 μg of nipradilol. At its highest dose, nipradilol achieved a reduction of 34.4 ± 4.4% in heart rate which was similar to that in the propranolol group (36.5 ± 2.4%). Also for other systemic haemodynamic parameters, the nipradilol 1200 μg group exhibited changes not significantly different from those in the propranolol group; mean arterial pressure (‐ 13 vs ‐ 14%), cardiac index (‐ 37 vs ‐ 31%) and systemic vascular resistance (+ 29 vs+ 32%). In contrast to the similar changes in the systemic circulation, a 1200 μg dose of nipradilol lowered portal pressure significantly more than propranolol (‐ 4.3 ± 0.6 vs ‐ 2.9 ± 0.2 mmHg, P≤ 0.05). Nipradilol then reduced portal blood flow by 22% (P≤ 0.05) without a significant change in portocollateral resistance. On the other hand, propranolol not only caused a reduction in portal blood flow of 30% (P≤ 0.01), but also an increase in portocollateral resistance of 21% (P≤ 0.05). The results suggest that nipradilol may ensure a more effective control of portal hypertension than propranolol, presumably via its venodilatory action on portocollateral vessels.

AB - The haemodynamic effects of nipradilol, a new non‐selective β‐adrenoreceptor blocker with vasodilating actions like nitroglycerin, were examined in rats with portal hypertension due to portal vein stenosis. Portal hypertensive rats were divided into five groups receiving infusion of placebo, 3 mg of propranolol, 300, 600 and 1200 μg of nipradilol. At its highest dose, nipradilol achieved a reduction of 34.4 ± 4.4% in heart rate which was similar to that in the propranolol group (36.5 ± 2.4%). Also for other systemic haemodynamic parameters, the nipradilol 1200 μg group exhibited changes not significantly different from those in the propranolol group; mean arterial pressure (‐ 13 vs ‐ 14%), cardiac index (‐ 37 vs ‐ 31%) and systemic vascular resistance (+ 29 vs+ 32%). In contrast to the similar changes in the systemic circulation, a 1200 μg dose of nipradilol lowered portal pressure significantly more than propranolol (‐ 4.3 ± 0.6 vs ‐ 2.9 ± 0.2 mmHg, P≤ 0.05). Nipradilol then reduced portal blood flow by 22% (P≤ 0.05) without a significant change in portocollateral resistance. On the other hand, propranolol not only caused a reduction in portal blood flow of 30% (P≤ 0.01), but also an increase in portocollateral resistance of 21% (P≤ 0.05). The results suggest that nipradilol may ensure a more effective control of portal hypertension than propranolol, presumably via its venodilatory action on portocollateral vessels.

KW - nipradilol

KW - portal hypertension

KW - propranolol

UR - http://www.scopus.com/inward/record.url?scp=0027234674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027234674&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1746.1993.tb01540.x

DO - 10.1111/j.1440-1746.1993.tb01540.x

M3 - Article

VL - 8

SP - 414

EP - 419

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 5

ER -